Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia |  |
|
Posted by BioSpace.com Featured News June 28th, 2009 .
| |
| No Comments |
SAN DIEGO, June 29 /PRNewswire/ -- Palkion, Inc. announced today that it has initiated preclinical development studies for its orally available anemia therapeutic candidate that modulates the Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PH) enzyme system. In February 2008, Palkion was founded when a novel drug discovery and development firm, CrystalGenomics (KOSDAQ: CRYSTAL [A083790]) and a...
See other entries categorized in BioSpace, News, Syndication.
Print This Post
.
Subscribe by RSS or email. Connect with San Diego Biotech professionals by joining the SDBN and attending our next event.
Print This Post
.
Subscribe by RSS or email. Connect with San Diego Biotech professionals by joining the SDBN and attending our next event.
